Back Bay in STAT: Early-Stage Price Setting

Christopher Leo, PhD and his team addressed price setting and market access planning for early-stage biopharma and medical device companies to an article published in STAT News.

Early price setting, other market access planning is key for early-stage drug, device companies examines the essential conversations for companies at ever-earlier stages of development. This work can affect the value of new treatments and shape conversations with investors, partners, or acquirers.

Subscribers can download and share the article at STAT Plus.